EcoDrugPlus

C-C Chemokine Receptor Type 1

Ensembl ID : ENSPEMG00000015252
Gene Symbol: LOC102922301
3 Cross references
291 Possible Orthologues:

C-C Chemokine Receptor Type 2

Ensembl ID : ENSPEMG00000007551
Gene Symbol: LOC102921374
3 Cross references
286 Possible Orthologues:

C-C Chemokine Receptor Type 5

Ensembl ID : ENSPEMG00000022837
Gene Symbol: LOC102921074
3 Cross references
298 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSPEMG00000022968
Gene Symbol: CCR9
3 Cross references
262 Possible Orthologues:

C-X-C Chemokine Receptor Type 1

Ensembl ID : ENSPEMG00000014090
Gene Symbol: LOC102912080
3 Cross references
158 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSPEMG00000019983
Gene Symbol: CXCR4
3 Cross references
283 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSPEMG00000008730
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSPEMG00000004880
Gene Symbol: DNMT1
2 Cross references
205 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSPEMG00000010015
Gene Symbol: TOP2B
3 Cross references
208 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSPEMG00000014979
Gene Symbol: EML4
3 Cross references
209 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSPEMG00000023679
Gene Symbol: EPHA2
3 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSPEMG00000021373
Gene Symbol: EPHA3
3 Cross references
215 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).